8-K: Sotera Health Appoints New CEO, Reports Strong Q1 2026 Results

Sotera Health announced a CEO transition and reported a strong first quarter of 2026 with significant revenue and Adjusted EBITDA growth, reaffirming its full-year outlook.

Summary

• Sotera Health Company reported its financial results for the quarter ended March 31, 2026, showing a strong performance with net revenues increasing by 10.0% (6.5% on a constant currency basis) compared to the first quarter of 2025.
• The company achieved a net income of $27 million, or $0.09 per diluted share, a significant improvement from a net loss of $13 million, or $0.05 per diluted share, in the prior year's first quarter.
• Adjusted EBITDA saw a 10.5% increase (6.9% on a constant currency basis), and Adjusted EPS rose by 29% to $0.18 per diluted share.
• Sotera Health is reaffirming its full-year 2026 financial outlook, projecting net revenue growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, both on a constant currency basis.
• A significant leadership change was announced: Alton Shader will become the new CEO and a Class II director, effective May 26, 2026, while Michael B. Petras, Jr. will transition to Executive Chairman.
• The company added two independent directors to its Board of Directors in February and March 2026, enhancing its governance and strategic oversight.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to strong Q1 results, improved profitability, and reaffirmed full-year guidance, despite a planned CEO transition and a slight dip in one segment.

Positives

• Net revenues increased by 10.0% to $280.0 million in Q1 2026, up from $254.5 million in Q1 2025.
• Net income turned positive at $26.6 million in Q1 2026, compared to a net loss of $13.3 million in Q1 2025.
• Diluted earnings per share improved to $0.09 in Q1 2026 from a loss of $0.05 in Q1 2025.
• Adjusted EBITDA grew by 10.5% to $134.7 million in Q1 2026, compared to $121.8 million in Q1 2025.
• Adjusted EBITDA margin improved slightly to 48.1% in Q1 2026 from 47.9% in Q1 2025.
• Adjusted EPS increased by 29% to $0.18 per diluted share in Q1 2026.
• Sterigenics segment revenue grew 9.7% to $186.1 million, with segment income up 9.6%.
• Nordion segment revenue grew 29.0% to $42.0 million, with segment income up 36.1% and margin improvement of over 290 basis points.
• Net cash provided by operating activities was $29.4 million in Q1 2026.
• The company reaffirmed its full-year 2026 outlook for net revenue growth (5.0%-6.5%) and Adjusted EBITDA growth (5.5%-7.0%), both on a constant currency basis.
• The Net Leverage Ratio remained stable at 3.2x as of March 31, 2026.
• Over $900 million in available liquidity was reported as of March 31, 2026.

Negatives

• Nelson Labs segment revenue decreased by 0.7% to $52.0 million in Q1 2026, with segment income down 11.5%.
• Net cash provided by operating activities decreased to $29.4 million in Q1 2026 from $55.5 million in Q1 2025.
• Capital expenditures increased significantly to $46.2 million in Q1 2026 from $19.9 million in Q1 2025.
• The company incurred a $30.9 million Illinois EO litigation settlement in Q1 2026, which impacted cash flows.

Risks

• Disruption in the availability or supply of, or increases in the price of, EO, Co-60 or other direct materials, services and supplies, including as a result of geopolitical instability.
• Fluctuations in foreign currency exchange rates.
• Evolving changes in environmental, health and safety regulations.
• Health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60.
• The impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from sterilization facilities.
• Allegations of failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm.
• Compliance with extensive regulatory requirements and potential delays in receiving required clearances or approvals.
• Adverse changes in industry trends, competition, and market conditions, including inflationary trends and tariffs.

Future Outlook

The company reaffirms its full-year 2026 outlook, projecting net revenues in the range of $1.233 billion to $1.251 billion (5.0% - 6.5% constant currency growth) and Adjusted EBITDA in the range of $632 million to $641 million (5.5% - 7.0% constant currency growth). Adjusted EPS is expected to be between $0.93 and $1.01. Capital expenditures are projected to be between $175 million and $225 million.

Management Comments

• "We delivered a strong start to the year, with solid revenue and Adjusted EBITDA growth while driving margin expansion. Growth was driven by disciplined execution at Sterigenics and Nordion, and Nelson Labs came in as we outlined on our fourth-quarter 2025 earnings call."
• "Based on our first-quarter performance, we are reaffirming our 2026 outlook and remain confident in our trajectory for the remainder of the year."
• "In addition to adding Rich Kyle to our Board of Directors in February, we are also excited to welcome Ken Krause, who joined our Board in March. Ken's leadership and proven track record of creating shareholder value as a public company chief financial officer for over 10 years, and his extensive experience in strategy, finance and governance will be tremendous assets as we continue to grow."

Industry Context

StockSavvy.ai notes that Sotera Health's strong Q1 2026 results, particularly in its Sterigenics and Nordion segments, align with a general trend of increased demand for healthcare sterilization and lab testing services. The company's reaffirmation of its full-year outlook suggests resilience in its core markets despite broader economic uncertainties.

Comparison to Industry Standards

• Sotera Health's Q1 2026 net revenue growth of 10.0% (6.5% constant currency) outpaces the projected growth for the broader healthcare services sector, which is estimated to be around 4-5% for 2026.
• The Adjusted EBITDA margin of 48.1% is robust and generally higher than many diversified healthcare service providers, reflecting the mission-critical nature of its sterilization services.
• While Nelson Labs experienced a slight revenue dip, the overall performance across Sterigenics and Nordion demonstrates strong execution, especially when compared to competitors facing supply chain pressures or regulatory headwinds in similar sub-sectors.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement of 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to a term sheet entered into on April 3, 2025.
• The company incurred a $30.9 million Illinois EO litigation settlement cost in Q1 2026.

Stakeholder Impact

• Shareholders: Positive impact from improved financial performance, increased net income, and reaffirmed full-year guidance. Leadership transition may introduce short-term uncertainty but aims for long-term stability.
• Employees: Potential impact from leadership changes. Compensation packages for new CEO are detailed, indicating investment in leadership.
• Creditors: Stable Net Leverage Ratio and significant liquidity provide comfort regarding debt obligations.

Next Steps

• Hold conference call on May 5, 2026, to discuss financial results.
• Attend RBC Capital Markets Global Healthcare Conference on May 19, 2026.
• Participate in the Sotera Health 2026 Annual Meeting of Stockholders on May 21, 2026.
• Attend the Jefferies Global Healthcare Conference on June 3, 2026.
• Attend the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.
• Alton Shader to assume CEO role effective May 26, 2026.
• Michael B. Petras, Jr. to transition to Executive Chairman effective May 26, 2026.

Key Dates

Recommendation

The company delivered expected strong Q1 results and reaffirmed guidance, indicating stability. However, the CEO transition introduces a period of adjustment, and while the outlook is positive, significant catalysts for immediate upside are not apparent in this filing alone. A 'hold' recommendation allows for observation of the new leadership's execution.

Keywords

Sotera Health, 8-K, SEC Filing, Sterigenics, Nordion, Nelson Labs, CEO Transition, Financial Results